NEW YORK (GenomeWeb) — Hologic said this week that its molecular diagnostics sales declined 8 percent year over year in its fiscal second quarter, but increased 1 percent when adjusted for the divestiture last year of its Lifecodes transplant diagnostics segment.

Hologic's adjusted growth in molecular diagnostics, which includes the company's Panther testing system and associated Aptima assays, helped mitigate an overall 2 percent decline in revenues, or 4 percent on adjusted basis, in its Diagnostics segment. Overall, the firm's revenues were up 2 percent year over year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.